Key Points
-
Atherosclerosis is characterized by lipid deposition and chronic inflammation, associated with immune activation and the induction of inflammatory mediators and signalling pathways
-
Putative therapeutic strategies specifically targeting chronic inflammation in atherosclerosis include classic anti-inflammatory drugs, biologic therapies targeting cytokines and chemokines, and small molecule enzyme inhibitors and receptor antagonists
-
Inducing immune tolerance through vaccination against atherosclerosis-associated immunogens can potentially offer an additional strategy for protection against atherosclerosis
-
Evidence in support of the use of anti-inflammatory therapies for atherosclerosis is mainly based on either observational or small interventional studies to evaluate surrogate markers of disease activity
-
Randomized controlled studies to evaluate the effect of specific anti-inflammatory strategies on cardiovascular outcomes are ongoing and might lead the way for additional therapeutic strategies
Abstract
The view of atherosclerosis as an inflammatory disease has emerged from observations of immune activation and inflammatory signalling in human atherosclerotic lesions, from the definition of inflammatory biomarkers as independent risk factors for cardiovascular events, and from evidence of low-density lipoprotein-induced immune activation. Studies in animal models of hyperlipidaemia have also supported the beneficial effects of countering inflammation to delay atherosclerosis progression. Specific inflammatory pathways with relevance to human diseases have been identified, and inhibitors of these pathways are either already in use for the treatment of other diseases, or are under development and evaluation. These include 'classic' drugs (such as allopurinol, colchicine, and methotrexate), biologic therapies (for example tumour necrosis factor inhibitors and IL-1 neutralization), as well as targeting of lipid mediators (such as phospholipase inhibitors and antileukotrienes) or intracellular pathways (inhibition of NADPH oxidase, p38 mitogen-activated protein kinase, or phosphodiesterase). The evidence supporting the use of anti-inflammatory therapies for atherosclerosis is mainly based on either observational or small interventional studies evaluating surrogate markers of disease activity. Nevertheless, these data are crucial to understand the role of inflammation in atherosclerosis, and to design randomized controlled studies to evaluate the effect of specific anti-inflammatory strategies on cardiovascular outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685–1695 (2005).
Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317–325 (2011).
Jonasson, L., Holm, J., Skalli, O., Gabbiani, G. & Hansson, G. K. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest. 76, 125–131 (1985).
Hansson, G. K., Hellstrand, M., Rymo, L., Rubbia, L. & Gabbiani, G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med. 170, 1595–1608 (1989).
Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135–1143 (2002).
Palinski, W. et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl Acad. Sci. USA 86, 1372–1376 (1989).
Stemme, S. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA 92, 3893–3897 (1995).
Mach, F., Schonbeck, U., Sukhova, G. K., Atkinson, E. & Libby, P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394, 200–203 (1998).
Nicoletti, A., Kaveri, S., Caligiuri, G., Bariety, J. & Hansson, G. K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Invest. 102, 910–918 (1998).
Hansson, G. K. & Hermansson, A. The immune system in atherosclerosis. Nat. Immunol. 12, 204–212 (2011).
Jonasson, L., Holm, J. & Hansson, G. K. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc. Natl Acad. Sci. USA 85, 2303–2306 (1988).
Marks, A. R. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N. Engl. J. Med. 349, 1307–1309 (2003).
Lutgens, E. et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J. Exp. Med. 207, 391–404 (2010).
Chatzigeorgiou, A. et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc. Natl Acad. Sci. USA 111, 2686–2691 (2014).
Cutolo, M., Sulli, A., Pizzorni, C., Seriolo, B. & Straub, R. H. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 60, 729–735 (2001).
Bulgarelli, A., Martins Dias, A. A., Caramelli, B. & Maranhao, R. C. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J. Cardiovasc. Pharmacol. 59, 308–314 (2012).
Westlake, S. L. et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 49, 295–307 (2010).
Micha, R. et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am. J. Cardiol. 108, 1362–1370 (2011).
Ahlehoff, O. et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J. Intern. Med. 273, 197–204 (2013).
Everett, B. M. et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am. Heart J. 166, 199–207.e15 (2013).
Nidorf, S. M., Eikelboom, J. W. & Thompson, P. L. Colchicine for secondary prevention of cardiovascular disease. Curr. Atheroscler. Rep. 16, 391 (2014).
Nuki, G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr. Rheumatol. Rep. 10, 218–227 (2008).
Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
Crittenden, D. B. et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J. Rheumatol. 39, 1458–1464 (2012).
Grimaldi-Bensouda, L. et al. Impact of allopurinol on risk of myocardial infarction. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-202972.
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A. & Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61, 404–410 (2013).
Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597–605 (2011).
Kaya, E. B. et al. Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography. Atherosclerosis 213, 178–183 (2010).
Higgins, P. et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc. Ther. 30, 217–226 (2012).
George, J., Carr, E., Davies, J., Belch, J. J. & Struthers, A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114, 2508–2516 (2006).
Kushiyama, A. et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler. Thromb. Vasc. Biol. 32, 291–298 (2012).
Noman, A., Ang, D. S., Ogston, S., Lang, C. C. & Struthers, A. D. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375, 2161–2167 (2010).
Rentoukas, E. et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int. J. Cardiol. 145, 257–258 (2010).
Topol, E. J. et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343, 881–886 (1994).
Wallberg-Jonsson, S., Ohman, M. L. & Dahlqvist, S. R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J. Rheumatol. 24, 445–451 (1997).
Holmqvist, M. E. et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum. 60, 2861–2869 (2009).
Taylor, P. C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578–582 (2009).
Jacobsson, L. T. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213–1218 (2005).
Dixon, W. G. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905–2912 (2007).
Bevilacqua, M. P., Pober, J. S., Majeau, G. R., Cotran, R. S. & Gimbrone, M. A. Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 160, 618–623 (1984).
Libby, P., Warner, S. J. & Friedman, G. B. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J. Clin. Invest. 81, 487–98 (1988).
Rajamaki, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).
Ridker, P. M. et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126, 2739–2748 (2012).
Lee, T. S., Yen, H. C., Pan, C. C. & Chau, L. Y. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19, 734–742 (1999).
Davenport, P. & Tipping, P. G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163, 1117–1125 (2003).
Yong, K. et al. Interleukin-12 is associated with arterial stiffness in healthy individuals. Am. J. Hypertens. 26, 159–162 (2013).
David, A. et al. Interleukin-23 serum levels in patients affected by peripheral arterial disease. Clin. Biochem. 45, 275–258 (2012).
Gistera, A. et al. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci. Transl. Med. 5, 196ra100 (2013).
Ryan, C. et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306, 864–871 (2011).
Tzellos, T., Kyrgidis, A. & Zouboulis, C. C. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. 27, 622–627 (2013).
Koenen, R. R. & Weber, C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol. Med. 3, 713–725 (2011).
Boring, L., Gosling, J., Cleary, M. & Charo, I. F. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894–897 (1998).
Gilbert, J. et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am. J. Cardiol. 107, 906–911 (2011).
Weber, C. et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J. Clin. Invest. 121, 2898–2910 (2011).
Burke, J. E. & Dennis, E. A. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid. Res. 50 (Suppl.), S237–S242 (2009).
Rosenson, R. S. & Gelb, M. H. Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr. Cardiol. Rep. 11, 445–451 (2009).
Suckling, K. E. Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin. Investig. Drugs 18, 1425–1430 (2009).
Rosenson, R. S. & Hurt-Camejo, E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur. Heart J. 33, 2899–2909 (2012).
Fraser, H. et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE−/− mice. J. Cardiovasc. Pharmacol. 53, 60–65 (2009).
Shaposhnik, Z., Wang, X., Trias, J., Fraser, H. & Lusis, A. J. The synergistic inhibition of atherogenesis in apoE−/− mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. 50, 623–629 (2009).
Rosenson, R. S. et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J. Am. Coll. Cardiol. 56, 1079–1088 (2010).
Nicholls, S. J. et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 311, 252–262 (2014).
Ait-Oufella, H. et al. Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 33, 466–473 (2013).
Tsimikas, S., Tsironis, L. D. & Tselepis, A. D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 27, 2094–2099 (2007).
Kolodgie, F. D. et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2523–2529 (2006).
Wilensky, R. L. et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 14, 1059–1066 (2008).
Serruys, P. W. et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1172–1182 (2008).
STABILITY Investigators. Darapladib for preventing ischemic events in stable coronary heart disease. N. Engl. J. Med. 370, 1702–1711 (2014).
O'Donoghue, M. L. et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID–TIMI 52 randomized clinical trial. JAMA 312, 1006–1015 (2014).
Capra, V., Bäck, M., Angiolillo, D. J., Cattaneo, M. & Sakariassen, K. S. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J. Thromb. Haemost. 12, 126–137 (2014).
Gabrielsen, A. et al. Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. J. Mol. Med. (Berl.) 88, 795–806 (2010).
Petri, M. H. et al. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 441, 393–398 (2013).
Bousser, M. G. et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 377, 2013–2022 (2011).
Stemme, V., Swedenborg, J., Claesson, H. & Hansson, G. K. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur. J. Vasc. Endovasc. Surg. 20, 146–152 (2000).
Bäck, M., Yin, L. & Ingelsson, E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur. Heart J. 33, 1928–1933 (2012).
Foudi, N. et al. Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits. Am. J. Physiol. Heart Circ. Physiol. 297, H1882–H1888 (2009).
Hui, Y. et al. Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation 121, 2654–2660 (2010).
Tang, S. Y. et al. Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice. Circulation 129, 1761–1769 (2014).
Babaev, V. R. et al. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 113, 108–117 (2006).
Rådmark, O. & Samuelsson, B. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem. Biophys. Res. Commun. 396, 105–110 (2010).
Bäck, M. et al. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br. J. Pharmacol. 171, 3551–3574 (2014).
Bäck, M. & Hansson, G. K. Leukotriene receptors in atherosclerosis. Ann. Med. 38, 493–502 (2006).
Nagy, E. et al. Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 123, 1316–1325 (2011).
Bäck, M., Gasser, T. C., Michel, J. B. & Caligiuri, G. Biomechanical factors in the biology of aortic wall and aortic valve diseases. Cardiovasc. Res. 99, 232–241 (2013).
Kwak, B. R. et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur. Heart J. 14, 3013–3020 (2014).
Otsuka, F., Sakakura, K., Yahagi, K., Joner, M. & Virmani, R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler. Thromb. Vasc. Biol. 34, 724–736 (2014).
Spanbroek, R. et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl Acad. Sci. USA 100, 1238–1243 (2003).
Allen, S., Dashwood, M., Morrison, K. & Yacoub, M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 97, 2406–2413 (1998).
De Caterina, R. et al. Sulfido-peptide leukotrienes in coronary heart disease—relationship with disease instability and myocardial ischaemia. Eur. J. Clin. Invest. 40, 258–272 (2010).
Labat, C. et al. Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis. J. Hypertens. 31, 2251–2258 (2013).
Stanke-Labesque, F. et al. Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J. Lipid Res. 53, 1944–1951 (2012).
Bäck, M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr. Pharm. Des. 15, 3116–3132 (2009).
Jawien, J. et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur. J. Clin. Invest. 36, 141–146 (2006).
Bäck, M., Sultan, A., Ovchinnikova, O. & Hansson, G. K. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. 100, 946–949 (2007).
Yu, Z. et al. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc. Natl Acad. Sci. USA 109, 6727–6732 (2012).
Bäck, M. et al. Leukotriene B4 signaling through NF-κB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc. Natl Acad. Sci. USA 102, 17501–17506 (2005).
Heller, E. A. et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 112, 578–586 (2005).
Hlawaty, H. et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler. Thromb. Vasc. Biol. 29, 518–524 (2009).
Mueller, C. F. et al. Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation 117, 2912–2918 (2008).
Allayee, H. et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest 132, 868–874 (2007).
Ingelsson, E., Yin, L. & Bäck, M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J. Allergy Clin. Immunol. 129, 702–707 e2 (2012).
Hakonarson, H. et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293, 2245–2256 (2005).
Tardif, J. C. et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ. Cardiovasc. Imaging 3, 298–307 (2010).
Liu, H. Q. et al. NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 33, 2193–2201 (2013).
Bitto, A. et al. Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques. J. Vasc. Surg. 52, 1015–1021 (2010).
Seeger, F. H. et al. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res. Cardiol. 105, 389–397 (2010).
Morris, J. B. et al. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler. Thromb. Vasc. Biol. 28, 265–271 (2008).
Fisk, M., Gajendragadkar, P. R., Maki-Petaja, K. M., Wilkinson, I. B. & Cheriyan, J. Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease. Am. J. Cardiovasc. Drugs 14, 155–165 (2014).
Sarov-Blat, L. et al. Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans. Arterioscler. Thromb. Vasc. Biol. 30, 2256–2263 (2010).
Natarajan, P. & Cannon, C. P. Could direct inhibition of inflammation be the “next big thing” in treating atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 30, 2081–2083 (2010).
Cheriyan, J. et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123, 515–523 (2011).
Elkhawad, M. et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc. Imaging 5, 911–922 (2012).
Melloni, C. et al. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am. Heart J. 164, 646–653.e3 (2012).
Newby, L. K. et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 384, 1187–1195 (2014).
Parmar, K. M. et al. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J. Biol. Chem. 280, 26714–26719 (2005).
Ali, F. et al. Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow. J. Biol. Chem. 284, 18882–18892 (2009).
van Thienen, J. V. et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc. Res. 72, 231–240 (2006).
Sorescu, D. et al. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation 105, 1429–1435 (2002).
Guzik, T. J. et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105, 1656–1662 (2002).
Sheehan, A. L. et al. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 216, 321–326 (2011).
Judkins, C. P. et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE−/− mice. Am. J. Physiol. Heart Circ. Physiol. 298, H24–H32 (2010).
Gray, S. P. et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127, 1888–1902 (2013).
Di Marco, E. et al. Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe−/− mice. Diabetologia 57, 633–642 (2014).
Iida, O. et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 127, 2307–2315 (2013).
Douglas, J. S. Jr et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112, 2826–2832 (2005).
Souness, J. E., Hassall, G. A. & Parrott, D. P. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 44, 857–866 (1992).
Ishizaka, N. et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 142, 41–46 (1999).
Takase, H. et al. Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimittelforschung 57, 185–191 (2007).
Beghe, B., Rabe, K. F. & Fabbri, L. M. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am. J. Respir. Crit. Care Med. 188, 271–278 (2013).
White, W. B. et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 144, 758–765 (2013).
Balarini, C. M. et al. Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. J. Transl. Med. 11, 3 (2013).
Xu, Q., Kleindienst, R., Waitz, W., Dietrich, H. & Wick, G. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J. Clin. Invest. 91, 2693–2702 (1993).
Palinski, W., Miller, E. & Witztum, J. L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl Acad. Sci. USA 92, 821–825 (1995).
Ameli, S. et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16, 1074–1079 (1996).
George, J. et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138, 147–152 (1998).
Zhou, X., Caligiuri, G., Hamsten, A., Lefvert, A. K. & Hansson, G. K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 108–114 (2001).
Ketelhuth, D. F., Gistera, A., Johansson, D. K. & Hansson, G. K. T cell-based therapies for atherosclerosis. Curr. Pharm. Des. 19, 5850–5858 (2013).
van Puijvelde, G. H. et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114, 1968–1976 (2006).
Klingenberg, R. et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30, 946–952 (2010).
Shah, P. K., Chyu, K., Dimayuga, P. C. & Nilsson, J. Vaccine for atherosclerosis. J. Am. Coll. Cardiol. 64, 2779–2791 (2014).
Xu, Q. et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12, 789–799 (1992).
George, J. et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler. Thromb. Vasc. Biol. 19, 505–510 (1999).
Maron, R. et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106, 1708–1715 (2002).
Ait-Oufella, H. et al. Measles virus nucleoprotein induces a regulatory immune response and reduces atherosclerosis in mice. Circulation 116, 1707–1713 (2007).
Ovchinnikova, O. A. et al. Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis. J. Intern. Med. 275, 49–58 (2014).
Acknowledgements
The authors are supported by the Swedish Research Council, the Swedish Heart and Lung Foundation, the Stockholm County Council, the European Commission, and the Linnaeus Center of Excellence for Research on Inflammation and Cardiovascular disease (CERIC).
Author information
Authors and Affiliations
Contributions
Both authors researched the data for the article, provided substantial contributions to discussions of its content, wrote the article, and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bäck, M., Hansson, G. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 12, 199–211 (2015). https://doi.org/10.1038/nrcardio.2015.5
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2015.5
This article is cited by
-
Functional role of Ash2l in oxLDL induced endothelial dysfunction and atherosclerosis
Cellular and Molecular Life Sciences (2024)
-
Exploring the underlying mechanisms of fisetin in the treatment of hepatic insulin resistance via network pharmacology and in vitro validation
Nutrition & Metabolism (2023)
-
GSDME-mediated pyroptosis promotes the progression and associated inflammation of atherosclerosis
Nature Communications (2023)
-
Two pyrrole acids isolated from Phyllanthus emblica L. and their bioactivities
Natural Products and Bioprospecting (2023)
-
Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway
Journal of Translational Medicine (2022)